Endometrial Cancer
GCT1184-03: A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator’s Choice (IC) in Patients with Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy
- Details
ClinicalTrials.gov ID:
NCT07166094
Diagnosis Type:
NA
USOR Number:
- Address
,
P: